Hemab Therapeutics Prices $301.5M IPO at $18/Share, Nasdaq Debut Set for May

Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company specializing in treatments for blood coagulation disorders, has priced its initial public offering at $18.00 per share, pricing an upsized offering of 16.75 million shares that will generate approximately $301.5 million in gross proceeds. The company's shares are scheduled to begin trading on the Nasdaq under the ticker symbol $COAG on May 1, 2026, with the offering expected to close on May 4, 2026.

The pricing represents a significant milestone for the clinical-stage biotech firm as it advances toward becoming a publicly traded company. The upsized offering—a positive indicator of investor demand—will provide Hemab with substantial capital to accelerate its development programs and expand operations as it works toward commercializing therapies for patients with blood coagulation disorders.

Key Details of the Offering

The $301.5 million IPO consists of the primary offering at $18.00 per share across the full allocation of 16.75 million shares. The scale of the offering represents an upsizing from the company's initial filing, a common occurrence when underwriters gauge strong institutional and retail investor interest during the book-building process.

Key metrics from the offering:

• Offer price: $18.00 per share
• Shares offered: 16.75 million shares
• Gross proceeds: ~$301.5 million
• Ticker symbol: $COAG
• Exchange: Nasdaq
• Expected trading date: May 1, 2026
• Expected closing date: May 4, 2026

The company's focus on blood coagulation disorder treatments positions it within the broader specialty pharma and rare disease treatment space, where unmet medical needs and limited competition can support premium valuations and stronger commercial potential once products reach the market.

Market Context and Industry Backdrop

Hemab's IPO timing occurs within a dynamic period for biotech fundraising. The clinical-stage biotechnology sector has experienced fluctuating investor sentiment in recent years, with companies demonstrating clinical progress and clear development pathways garnering stronger capital market reception.

The blood coagulation disorder treatment space represents a meaningful therapeutic area with significant patient populations. Conditions affecting blood coagulation carry substantial morbidity and mortality risks, creating strong clinical justification and market demand for innovative therapies. The company's clinical-stage focus indicates it is advancing candidates through development, though product approvals remain pending.

The biotech IPO market dynamics:

• Clinical-stage companies targeting rare and specialty diseases continue to attract investor capital
• The coagulation disorder space remains relatively consolidated, with opportunities for differentiated therapeutics
• Nasdaq represents the traditional home for biotechnology listings, providing appropriate market placement for $COAG
• Recent years have seen selective biotech IPO activity, with investor preference for companies with clear clinical data and development pathways

The company's upsized offering suggests positive reception from institutional investors and underwriters, indicating confidence in Hemab's therapeutic approach and capital allocation plans.

Investor Implications and Strategic Significance

For investors, Hemab's public market entry provides exposure to the specialty pharmaceutical and rare disease treatment sectors. The $301.5 million in gross proceeds will supply the company with working capital for:

• Advancing clinical development programs
• Potentially initiating new studies or expanding ongoing trials
• Building out commercial and operational infrastructure
• Funding general corporate operations and working capital needs

The IPO also establishes public liquidity for early-stage investors and provides a mechanism for ongoing capital raises should additional funding become necessary as development programs progress.

Key considerations for shareholders and market observers:

• Development risk: As a clinical-stage company, Hemab faces inherent risks associated with drug development timelines, regulatory approval, and clinical efficacy validation
• Capital efficiency: The substantial IPO proceeds provide runway for multiple development milestones
• Market opportunity: Blood coagulation disorders represent addressable markets with limited competition in certain segments
• Competitive landscape: Investors should monitor the broader field of coagulation disorder treatments and potential competitor pipeline advances

The $COAG ticker symbol directly references the company's therapeutic focus, providing market participants with instant recognition of its business specialization.

Looking Forward

Hemab Therapeutics enters the public markets at a pivotal juncture, with fresh capital and enhanced operational flexibility ahead of what will likely be a multi-year development timeline. The company's ability to execute on its clinical programs, meet regulatory timelines, and ultimately advance therapies toward commercialization will determine shareholder value creation from this juncture forward.

With trading expected to commence on May 1, 2026, public market investors will gain real-time visibility into the company's progress, clinical developments, and strategic initiatives. The $301.5 million capital raise positions Hemab to maintain momentum in its development efforts while maintaining the financial runway necessary to navigate the complex biotechnology landscape. For investors with theses around specialty pharma and coagulation disorder treatment innovation, the company's public market debut warrants close monitoring of its clinical pipeline and quarterly updates.

The biotech sector will continue watching how Hemab deploys its IPO capital and the progress of its clinical candidates—outcomes that will serve as important indicators for future special-purpose biotech fundraising activity.